Not sexy enough: the uphill battle faced by non‐traditional treatments in the U.S. despite having the most compelling AD results to date

The most followed investigational treatments for Alzheimer’s disease are small molecules (80/140 in development, 57%) and immunotherapies (32/140, 23%). These treatments have a clear regulatory path and are based on innovative scientific approaches that are generally patentable and marketable. The remaining 20% (28/140) of therapeutic approaches involve procedures, devices, supplements, combination treatments and others.